(Q34624096)

3 August 2017

title

The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis (English)

1 reference

peritoneal carcinomatosis

3 August 2017

1 reference

1 reference

Michael A Ströhlein

1

1 reference

3 August 2017

Markus M Heiss

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

3 August 2017

1 reference

3 August 2017

volume

6

1 reference

3 August 2017

issue

9

1 reference

3 August 2017

page(s)

1387-1394

1 reference

Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Malignant ascites: a 2-year review from a teaching hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

[Systemic treatment of peritoneal metastases].

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Frequent EpCam protein expression in human carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Bispecific antibodies targeting cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

A revival of bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Intraperitoneal immunotherapy to prevent peritoneal carcinomatosis in patients with advanced gastrointestinal malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Immunotherapy of malignant ascites with trifunctional antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.111

21 January 2018

Identifiers

DOI

10.2217/FON.10.111

1 reference

3 August 2017

1 reference